2.4.0.84023 - Disclosure - Summary of Significant Accounting Policies (Details 4)truefalsefalse1false falsefalseD2012http://www.sec.gov/CIK0001436304duration2012-01-01T00:00:002012-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0ItemStandardhttp://www.kytherabiopharma.com/20121231itemkyth02false falsefalseD2011http://www.sec.gov/CIK0001436304duration2011-01-01T00:00:002011-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli03false USDfalsefalse$D2010http://www.sec.gov/CIK0001436304duration2010-01-01T00:00:002010-12-31T00:00:00SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0ItemStandardhttp://www.kytherabiopharma.com/20121231itemkyth0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$I2010Q1_M0331http://www.sec.gov/CIK0001436304instant2010-03-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 2us-gaap_RevenueRecognitionAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Revenue Recognition2false 3kyth_NumberOfCriteriaToBeSatisfiedForRecognizingRevenuekyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse44falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of criteria to be satisfied for recognizing revenue by the entity in the financial statements.No definition available.false256Number of criteria to recognize revenue3false 3kyth_MaximumNumberOfElementsForWhichNoEvaluationIsRequiredForTheirTreatmentAsSeparateUnitOfAccountingkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse11falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the maximum number of elements for which no evaluation is required to determine their treatment as a separate unit of accounting.No definition available.false256Maximum number of elements for which no evaluation is required for their treatment as a separate unit of accounting4true 2us-gaap_OtherIncomeAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Other income5false 3kyth_AmountOfOneTimePoolEstablishedForGrantsToSmallBiotechCompanieskyth_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse10000000001000000000USD$falsetruefalsexbrli:monetaryItemTypemonetaryRepresents the amount of a one-time pool established through healthcare reform legislation for grants to small biotech entities developing novel therapeutics.No definition available.false2Amount of one-time pool established for grants to small biotech companies developing novel therapeutics6false 3us-gaap_RevenueFromGrantsus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse930000930000falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRevenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2Non-recurring grant received related to research and development projects7false 3kyth_NumberOfResearchAndDevelopmentProjectsFromWhichNonRecurringGrantWasReceivedkyth_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse44falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of research and development projects from which non-recurring grant was received by the entity during the period.No definition available.false256Number of research and development projects from which non-recurring grant was received8true 2us-gaap_EarningsPerShareAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Basic and Dilutive Net Loss Per Common Share9false 3us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse19560001956000falsefalsefalse2truefalsefalse1333400013334000falsefalsefalse3truefalsefalse1048100010481000falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 40 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 13, 14 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 07-4 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 128 -Paragraph 171 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false1Shares excluded from the calculation of net loss per common share10false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5false USDtruefalse$D2010_LicenseAgreementMemberhttp://www.sec.gov/CIK0001436304duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseLicense agreementus-gaap_TypeOfArrangementAxisxbrldihttp://xbrl.org/2006/xbrldikyth_LicenseAgreementMemberus-gaap_TypeOfArrangementAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse0License agreement11true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaboration Arrangements12false 4kyth_NonRefundableUpfrontLicenseFeeReceivedkyth_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse2131900021319000USD$falsetruefalse4falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the non-refundable upfront license fee received by the entity during the period.No definition available.false2Non-refundable upfront license fee from BayerfalseSummary of Significant Accounting Policies (Details 4) (USD $)NoRoundingNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://www.kytherabiopharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4412